中国现代医学杂志Issue(2)：29-32,4.DOI:10.3969/j.issn.1005-8982.2016.02.006
急性髓系白血病中乳腺癌耐药蛋白基因表达与临床意义*
Expression of gene and its clinical significance in patients with acute myeloid leukemia
摘要
Abstract
Objective To explore the expression and prognostic value of breast cancer resistance protein (BCRP) gene in acute myeloid leukemia (AML). Methods Real time quantitative polymerase chain reaction (RT-PCR) method was performed to detect the mRNA of BCRP in AML group (n=60) and non-hematologic malignancy group ( =20). The difference in the expression of both groups was studied and its correla-tion with clinical effect was analyzed. Results The gene expression level in the AML patients was sta-tistically higher than that in the control group (P<0.01). Significant difference was found among the newly-diagnosed AML group, the relapsed AML group and the complete remission (CR) AML group and the control group ( <0.01). The gene expression level was different in different disease stages with the highest lev-el in the relapsed group and the lowest in the complete-remission group. Conclusions BCRP gene expression increases in AML patients. The expression level of gene can be a useful biomarker for evaluation of AML progression, and may be an independent risk factor of AML.关键词
急性髓系白血病/BCRP基因/危险因素Key words
AML/breast cancer resistance protein gene/risk factor分类
医药卫生引用本文复制引用
李薇,周明,罗科玲,谭熹,雷平,邹彬宾..急性髓系白血病中乳腺癌耐药蛋白基因表达与临床意义*[J].中国现代医学杂志,2016,(2):29-32,4.基金项目
湖南省科技厅科技项目 （）
